Salehi-had, Hani |
| Active, not recruiting | 3 | 388 | Europe, US, RoW | HLX04-O, ranibizumab | Shanghai Henlius Biotech | Age Related Macular Degeneration | 12/24 | 03/25 | | |
| Recruiting | 3 | 560 | US | Fenofibrate, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust | Diabetic Retinopathy | 04/29 | 04/29 | | |
LEOPARD, NCT05608837: Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema |
|
|
| Recruiting | 2 | 24 | US | OCS-01, dexamethasone ophthalmic suspension eye drops | Quan Dong Nguyen, Global Ophthalmic Research Center (GORC), Oculis | Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative | 01/25 | 04/25 | | |
GION, NCT06178055: A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) |
|
|
| Recruiting | 2 | 75 | US | KUS121 high dose, KUS121 low dose, Sham procedure | Kyoto Drug Discovery and Development Co., Ltd. | Central Retinal Artery Occlusion | 12/24 | 09/25 | | |
| Recruiting | 2 | 128 | US | Tonabersat, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Diabetic Macular Edema | 11/24 | 05/25 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin, Inc. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin, Inc. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
| Recruiting | N/A | 400 | US | Immediate Vitrectomy, Deferred Vitrectomy | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Epiretinal Membrane | 12/26 | 12/26 | | |
Liu, Alex |
NCT06329791: A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) |
|
|
| Active, not recruiting | 3 | 500 | US | AZR-MD-001, AZR-MD-001 ophthalmic ointment 0.5%, Vehicle, AZR-MD-001 Vehicle | Azura Ophthalmics, ORA, Inc. | Dry Eye Disease | 12/24 | 11/25 | | |
NCT05895500: Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia |
|
|
| Completed | 2a | 103 | US | Injection for SC administration (120mg/syringe), Tablet (50mg/tablet), oral | Nvision Laser Eye Centers | Dry Eye, Asthenopia | 11/23 | 11/23 | | |
Ahn, Eric |
NCT05895500: Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia |
|
|
| Completed | 2a | 103 | US | Injection for SC administration (120mg/syringe), Tablet (50mg/tablet), oral | Nvision Laser Eye Centers | Dry Eye, Asthenopia | 11/23 | 11/23 | | |